Recent clinical trial data has catalyzed significant policy changes regarding respiratory syncytial virus prevention. New England Journal of Medicine research demonstrates that RSV vaccines reduce severe lower respiratory tract disease by 83 percent in adults aged 60 and older, providing compelling evidence for expanded vaccination strategies.
Building on this efficacy data, public health programs have broadened eligibility to include adults aged 50 and older with chronic health conditions such as heart disease, lung disease, and diabetes. The evidence-based approach reflects recognition that younger adults with comorbidities face comparable hospitalization risks to older, healthier populations.
These clinical findings have prompted healthcare systems to implement new vaccine deployment protocols, removing cost barriers and expanding access across multiple jurisdictions. Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Key Finding
📰 Read the full article: New RSV Vaccines Transform Prevention Strategies for Older Adults →
